» Articles » PMID: 9806368

Predictors of Lymphoma Development in Primary Sjögren's Syndrome

Overview
Specialty Rheumatology
Date 1998 Nov 7
PMID 9806368
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the clinical and laboratory predictors of lymphoma development in primary Sjögren's syndrome (pSS).

Methods: Seventy-two patients with pSS were studied. Demographic data, clinical features, serum gamma-globulin levels, autoantibodies, and HLA status were reviewed. For statistical analysis, Mann-Whitney U-test, Fisher's exact test, logistic regression analysis, Kaplan-Meier method, and log-rank tests were applied.

Results: Five patients developed a distinct non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue (MALT). A history of swollen salivary glands, lymphadenopathy, and leg ulcers predicted lymphoma development.

Conclusion: Patients with pSS are at increased risk of lymphoma development, and those who have the above risk factors must be carefully observed.

Citing Articles

Lymphadenopathy in the rheumatology practice: a pragmatic approach.

Rodolfi S, Della-Torre E, Bongiovanni L, Mehta P, Fajgenbaum D, Selmi C Rheumatology (Oxford). 2023; 63(6):1484-1493.

PMID: 38109670 PMC: 11147542. DOI: 10.1093/rheumatology/kead644.


Lymphomagenesis predictors and related pathogenesis.

Ruiz-Ordonez I, Piedrahita J, Arevalo J, Agualimpia A, Tobon G J Transl Autoimmun. 2021; 4:100098.

PMID: 33889831 PMC: 8050773. DOI: 10.1016/j.jtauto.2021.100098.


Pathogenetic Mechanisms Implicated in Sjögren's Syndrome Lymphomagenesis: A Review of the Literature.

Stergiou I, Poulaki A, Voulgarelis M J Clin Med. 2020; 9(12).

PMID: 33255258 PMC: 7759999. DOI: 10.3390/jcm9123794.


Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome.

Nayar S, Campos J, Smith C, Iannizzotto V, Gardner D, Colafrancesco S Ann Rheum Dis. 2018; 78(2):249-260.

PMID: 30472652 PMC: 6352416. DOI: 10.1136/annrheumdis-2017-212619.


Is primary Sjögren's syndrome a risk factor for malignancies different from lymphomas? What does the literature highlight about it?.

Manzo C, Kechida M Reumatologia. 2017; 55(3):136-139.

PMID: 28769137 PMC: 5534508. DOI: 10.5114/reum.2017.68913.